| Literature DB >> 31049593 |
Aleksander Kuriata1, Valentin Iglesias2, Jordi Pujols2, Mateusz Kurcinski1, Sebastian Kmiecik1, Salvador Ventura2.
Abstract
Protein aggregation is a hallmark of a growing number of human disorders and constitutes a major bottleneck in the manufacturing of therapeutic proteins. Therefore, there is a strong need of in-silico methods that can anticipate the aggregative properties of protein variants linked to disease and assist the engineering of soluble protein-based drugs. A few years ago, we developed a method for structure-based prediction of aggregation properties that takes into account the dynamic fluctuations of proteins. The method has been made available as the Aggrescan3D (A3D) web server and applied in numerous studies of protein structure-aggregation relationship. Here, we present a major update of the A3D web server to version 2.0. The new features include: extension of dynamic calculations to significantly larger and multimeric proteins, simultaneous prediction of changes in protein solubility and stability upon mutation, rapid screening for functional protein variants with improved solubility, a REST-ful service to incorporate A3D calculations in automatic pipelines, and a new, enhanced web server interface. A3D 2.0 is freely available at: http://biocomp.chem.uw.edu.pl/A3D2/.Entities:
Year: 2019 PMID: 31049593 PMCID: PMC6602499 DOI: 10.1093/nar/gkz321
Source DB: PubMed Journal: Nucleic Acids Res ISSN: 0305-1048 Impact factor: 16.971
Figure 1.The pipeline of Aggrescan3D 2.0 server.
Figure 2.Aggregation propensity for different multimeric proteins, calculated in static or dynamic modes. (A) The aggregation propensity of the static input structure relative to that of the 12 dynamic models is represented for homodimers, heterodimers, antibodies or the complete set. In the color scale, dark blue indicates the static structure being the most soluble (ranking 1) and dark red the static structure being the most aggregation-prone (ranking 13). (B) Monoclonal antibody bevacizumab Fab fragment (PDB: 1BJ1) ran on static (left) or dynamic (right) modes.
Figure 3.A3D 2.0 as a tool for the in silico redesign of more stable and soluble proteins. A3D structures of original GFP (left) (PDB: 2B3Q:A) and engineered GFP/KKK mutant (right) (PDB: 6FWW) coloured according to the A3D score. Mutations lowering aggregation propensity, while maintaining protein stability are encircled. The mutated variant was experimentally shown to be 2-fold more resistant against aggregation (19).
Figure 4.Automated mutations for variable heavy (VH) segment of a human germline antibody. (A) A3D 2.0 automated mutations output (the residues at the three antibody CDRs were excluded from the screening). (B) The blue highlighted mutations in panel A were combined to render triple mutant engineered antibody. Structures of wild type (PDB: 5I19) and the mutant, as predicted by A3D 2.0. Solubilizing mutations are encircled. The engineered antibody variant was experimentally shown to be 3-fold more resistant against aggregation (19).